Publications (217) Publications in which a researcher has participated

2023

  1. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program

    European Journal of Haematology, Vol. 111, Núm. 2, pp. 293-299

  2. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  3. Expert opinion paper on the treatment of hemophilia a with emicizumab

    Hematology (Amsterdam, Netherlands), Vol. 28, Núm. 1, pp. 2166334

  4. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

    Journal of Thrombosis and Haemostasis

  5. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations

    Microbiology spectrum, Vol. 11, Núm. 4, pp. e0067423

  6. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

    British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871

  7. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  8. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project

    Orphanet Journal of Rare Diseases, Vol. 18, Núm. 1

  9. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

  10. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  11. Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 3, pp. 177-179

  12. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799